Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies.

@article{Zhou2009RiskbasedSF,
  title={Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies.},
  author={Honghui Zhou and Hugh M. Davis},
  journal={Drug discovery today},
  year={2009},
  volume={14 17-18},
  pages={891-8}
}
Biological agents are used to treat a variety of diseases in many therapeutic areas, including oncology, rheumatology, gastroenterology, dermatology, respiratory disease, hormone deficiency and infection. While biologics constitute many of the recently approved new therapies, clinical research of drug-drug interactions with biologics has been scant. This review presents a risk-based assessment strategy for evaluating drug-drug interactions with monoclonal antibodies, a predominant class of… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Mechanisms of monoclonal antibody-drug interactions.

Annual review of pharmacology and toxicology • 2011

Similar Papers

Loading similar papers…